TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20126902
Drug: TR- (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR- (no treatment for periodontal disease)
Study: 17003306
Drug: Pioglitazone (PIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (PIO group; 45 mg/day)
Study: 7770136
Drug: Alkalinizing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinizing therapy (group I)
Study: 7770136
Drug: L-carnitine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (group II)
Study: 7770136
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (group III)
Study: 31585725
Drug: Vi-DT (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-DT (25 µg)
Study: 30880698
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with lopinavir/ritonavir plus lamivudine (DT group)
Study: 30880698
Drug: Chinese first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese first-line triple-therapy regimen (TT group)
Study: 28882910
Drug: Locally produced
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally produced lipid-based nutrient supplement (LNS)
Study: 26882609
Drug: Common treatment
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common treatment group
Study: 20861583
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30-70 mg/day
Study: 19032135
Drug: Ciprofloxacin otic
Normalized name: ciprofloxacin otic
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin otic solution 0.2% (twice daily for 7 days)
Study: 19032135
Drug: Polymyxin B-neomycin-hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (3 times daily for 7 days)
Study: 19032135
Drug: Ciprofloxacin otic
Normalized name: ciprofloxacin otic
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin otic solution 0.2% (for patients with P. aeruginosa)
Study: 19032135
Drug: Polymyxin B-neomycin-hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with P. aeruginosa)
Study: 19032135
Drug: Ciprofloxacin otic
Normalized name: ciprofloxacin otic
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin otic solution 0.2% (for patients with S. aureus)
Study: 19032135
Drug: Polymyxin B-neomycin-hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with S. aureus)
Study: 383274
Drug: 1-phenylalanine mustard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-phenylalanine mustard (L-PAM)
Study: 3886395
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg plus codeine 60 mg
Study: 24612093
Drug: 10-day hybrid
Normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 10 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Study: 24612093
Drug: 12-day hybrid
Normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 12 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Study: 24612093
Drug: 14-day hybrid
Normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 14 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Study: 19606244
Drug: 0.1 N
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 N hydrochloric acid (HCl) infusion
Study: 17621237
Drug: Darunavir (TMC114)
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir (TMC114) with low-dose ritonavir (600/100 mg twice daily)
Study: 15590214
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogen combined with 5 mg medroxyprogesterone acetate
Study: 15590214
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg transdermal estrogen alone
Study: 10022995
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin (70 mg/m2) and intravenous carboplatin (target AUCs of 4, 5, 6, and 7) with G-CSF (50 microgram/m2 from day 7 to 16)
Study: 2647846
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg once daily)
Study: 29541862
Drug: Desmopressin acetate
Normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin acetate nasal spray (0.1 mg/ml, 10 μg/spray) once daily for 10 days
Study: 29541862
Drug: Desmopressin acetate
Normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin acetate nasal spray
Study: 29757889
Drug: 3-signal T-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-signal T-cell activation (T-cell receptor activation, CD137/4-1BB stimulation, interleukin-2)
Study: 27358142
Drug: Lactulose oral
Normalized name: lactulose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose oral solution, 15 ml once a day, maintenance dose of 515 ml/time as needed, treatment lasted for six weeks.
Study: 24768330
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (IM) treatment alone (Arm B)
Study: 10096462
Drug: Add-back hormone
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-back hormone replacement therapy (HRT)
Study: 10096462
Drug: High-dose progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose progestogen
Study: 10096462
Drug: Low-dose progestogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose progestogen plus cyclical etidronate
Study: 10096462
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and low-dose HRT add-back
Study: 10096462
Drug: Low-dose and
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose and standard-dose add-back HRT
Study: 7000239
Drug: Sauna (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sauna (twice for 25 minutes at 85 degrees C)
Study: 29973367
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose level ≥200 mg/dL in participants with known diabetes
Study: 30098071
Drug: Once-daily, prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, prolonged-release tacrolimus (PR-T)
Study: 30098071
Drug: Twice-daily, immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily, immediate-release tacrolimus (IR-T)
Study: 15175957
Drug: Postoperative two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia reduced from 3 courses to 1 course
Study: 15175957
Drug: Post-chemotherapy blastemal
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy blastemal predominant subtype
Study: 11597384
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care protocol intervention (tooth brushing, 0.2% chlorhexidine mouth rinse, 0.9% saline rinse)
Study: 11597384
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral care protocol)
Study: 9589757
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment (ACT)
Study: 29127458
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (IV; 0.2-120 mg)
Study: 29127458
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (SC; 40-120 mg)
Study: 29127458
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (IV; doses ≥ 20 mg)
Study: 29127458
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (SC; 120 mg)
Study: 26531051
Drug: Topical natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical natamycin
Study: 20420756
Drug: Convenience drink
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Convenience drink supplemented with n‐3 fatty acids (200 mg EPA and 300 mg DHA)
Study: 20420756
Drug: Placebo (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.1 g linoleic acid from maize oil)
Study: 15970792
Drug: FSH dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH dose of 150 U/day (Group I, Ser/Ser)
Study: 15970792
Drug: FSH dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH dose of 225 U/day (Group II, Ser/Ser)
Study: 15970792
Drug: FSH dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH dose of 150 U/day (Group III, Asn/Asn)
Study: 10589812
Drug: Instructional leaflet
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Instructional leaflet (group L)
Study: 9107182
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg BID)
Study: 23047595
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose telmisartan (80 mg/day) combined with trichlormethiazide (1 mg/day)
Study: 23047595
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of telmisartan (40 mg/day), trichlormethiazide (1 mg/day), and amlodipine (5 mg/day)
Study: 12628899
Drug: Distraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distraction therapy with nature sights and sounds (nature scene murals and nature sounds tape)
Study: 10669333
Drug: Potent antiretroviral
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent antiretroviral therapy (protease inhibitor‐containing)
Study: 2023702
Drug: High-dose prochlorperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prochlorperazine infusion and dexamethasone (HDPD)
Study: 2023702
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide and dexamethasone (HDMD)
Study: 7067184
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release metoprolol (200 mg durule)
Study: 7067184
Drug: Conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metoprolol (100 mg twice daily)
Study: 28498078
Drug: Patient self-administration
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-administration of Kinetic Oscillatory Stimulation (KOS) catheter
Study: 28498078
Drug: Patient self-administration
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-administration of KOS catheter
Study: 25296740
Drug: Cryo-chamber therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo-chamber therapy at -67 °C
Study: 25296740
Drug: Sham cryo-chamber
Normalized name: HOLDING CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham cryo-chamber therapy at -5 °C
Study: 23819221
Drug: Electroacupuncture (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (1 Hz/50 Hz) for 30 min once daily for 14 days
Study: 23819221
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg/kg for first 3 days, 0.2 mg/kg for 7 days, 0.1 mg/kg afterwards)
Study: 23819221
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication (mild hypothermia, dehydration medicines, hormonal therapy, vascular dilation, cerebral nutrition, anti-inflammation)
Study: 19167143
Drug: Inadequate social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate social support, unstable job, and the use of alcohol and drugs
Study: 27835716
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) treatment
Study: 9121502
Drug: Anti-GM1 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-GM1 antibodies
Study: 9121502
Drug: Anti-GQ1b antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-GQ1b antibodies
Study: 9121502
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with anti-GM1 antibodies
Study: 9121502
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with anti-GQ1b antibodies
Study: 8002061
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of hydrocortisone (20 mg/m2 daily)
Study: 8002061
Drug: Night dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night dose of hydrocortisone (20 mg/m2 daily)
Study: 3042841
Drug: Naloxone HCl
Normalized name: naloxone HCl
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone HCl 2.0 mg/kg IV bolus
Study: 3042841
Drug: Naloxone HCl
Normalized name: naloxone HCl
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone HCl 0.1 mg/kg IV bolus
Study: 25402372
Drug: metformin 1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 1700 mg/d plus vildagliptin 100 mg/d
Study: 25402372
Drug: metformin 1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 1700 mg/d
Study: 9364693
Drug: Maternal HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal HBV DNA < 150 pg ml-1
Study: 9364693
Drug: Maternal HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal HBV DNA > 150 pg ml-1
Study: 1551035
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg twice daily
Study: 29580640
Drug: EasySix™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EasySix™ vaccine
Study: 27559737
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection (pain)
Study: 22828857
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (0.05-0.125 μg/kg/min) and propofol (1-3 mg/kg/h)
Study: 22828857
Drug: Propofol (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1-3 mg/kg/h)
Study: 20653166
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (dissolving phlegm-stasis)
Study: 16275486
Drug: Betaxolol hydrochloride
Normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaxolol hydrochloride (5 mg daily for 3 weeks)
Study: 12175392
Drug: tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine 2 mg twice daily for 10 weeks
Study: 12175392
Drug: oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxybutynin 5 mg twice daily for 10 weeks
Study: 10442207
Drug: sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained release capsules containing 100 mg tramadol hydrochloride, total of 6 capsules at intervals of 12 h
Study: 10442207
Drug: instant release
Approvals — FDA: no, EMA: no, PMDA: no
Description: instant release capsules containing 50 mg tramadol hydrochloride, total of 12 capsules at intervals of 6 h
Study: 7598920
Drug: eltanolone 0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: eltanolone 0.58 mg/kg
Study: 7598920
Drug: propofol 1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 1.7 mg/kg
Study: 29373884
Drug: Progesterone suppositories
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone suppositories (400 mg per night) until delivery or completion of the 34th gestational week
Study: 26480548
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy at Shenmen (HT 7), Baihui (GV 20), Yintang (GV 29), Hegu (LI 4), Taichong (LR 3), needles retained for 20 min, treatment once a day for 2 weeks (1 session).
Study: 26480548
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of trazodone, 100 mg, once a day for 2 weeks (1 session).
Study: 23567596
Drug: P. ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. ginseng (100 mg/d)
Study: 23567596
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg/d)
Study: 21766893
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a greater chance of success
Study: 21766893
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with lower cost
Study: 21766893
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with shorter duration before being able to exercise free of pain
Study: 21766893
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with lower chance of side effects
Study: 21766893
Drug: Injections as
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections as a stand-alone treatment
Study: 21766893
Drug: 10% increase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% increase in chance of treatment success
Study: 11574347
Drug: Midazolam (0.025,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.025, 0.05, and 0.1 mg/kg)
Study: 11574347
Drug: Propofol (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.25, 0.5, and 1.0 mg/kg)
Study: 9693434
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (non-NPPV)
Study: 29688873
Drug: Dialectical Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavioural Therapy (DBT) for 12 weeks
Study: 21736507
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral rTMS
Study: 18575851
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg orally
Study: 12218529
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion (0.2 mg/kg bolus followed by 3, 5, or 7 microg/kg/min infusion)
Study: 8599955
Drug: 99mTc-labelled antibodies
Normalized name: technetium (99mTc) antiCarcinoEmbryonicAntigen antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-labelled antibodies against granulocyte non-specific cross-reacting antigen-95
Study: 1924659
Drug: mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (30 mg to 150 mg)
Study: 1924659
Drug: amitriptyline (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline (60 mg to 300 mg)
Study: 1924659
Drug: placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (1 to 5 capsules at bedtime)
Study: 7051248
Drug: Parenteral trimethoprim‐sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral trimethoprim‐sulfamethoxazole and carbenicillin (TMP‐SMZ‐C)
Study: 7051248
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and carbenicillin (G‐C)
Study: 29398152
Drug: Daily online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily online CBCT IGRT (7 mm margins to PTV)
Study: 29398152
Drug: Weekly offline
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly offline portal imaging (15 mm margins to PTV)
Study: 22485048
Drug: Coad (ACWY-TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coad (ACWY-TT with seasonal influenza vaccine)
Study: 20331579
Drug: 5 apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 apheresis treatments
Study: 20331579
Drug: 10 apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 apheresis treatments
Study: 12900242
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment for 3+ cataracts
Study: 12900242
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment for 4+ cataracts
Study: 12900242
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment for all cataract densities
Study: 10919019
Drug: Self-expanding metal
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-expanding metal stent with initial laser therapy (group 2a)
Study: 30621948
Drug: Device therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device therapy in women
Study: 29526837
Drug: Core and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core and mobility training (EG; n=8) - 2 weekly sessions of 50 minutes for 10 weeks
Study: 26681684
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy with letrozole (arm A)